Alliance Pharma PLC Notification of Interim Results (9047F)
August 02 2016 - 2:01AM
UK Regulatory
TIDMAPH
RNS Number : 9047F
Alliance Pharma PLC
02 August 2016
For immediate release 2 August 2016
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Notification of Interim Results
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical
company, will announce its interim results for the six months ended
30 June 2016 on Wednesday 14 September 2016.
A briefing for analysts will be held at 9.30am on the morning of
the results at the offices of Buchanan, 107 Cheapside, London EC2V
6DN.
For more information, or to register attendance, please contact
Buchanan on 020 7466 5000.
For further information:
Alliance Pharma plc + 44 (0) 1249 466966
John Dawson, Chief Executive
Andrew Franklin, Chief Financial
Officer
Sarah Robinson, Company Secretary
Buchanan + 44 (0) 20 7466 5000
Mark Court / Sophie Cowles / Jane
Glover
Numis Securities Limited + 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade
/ Freddie Barnfield
Corporate Broking: James Black/ Toby
Adcock
Notes to editors:
About Alliance Pharma
Alliance, founded in 1998, is an international speciality
pharmaceutical company based in Chippenham, Wiltshire, UK. The
Company has sales in more than 100 countries worldwide via direct
sales, joint ventures and a network of distributors. Alliance has a
strong track record of acquiring the rights to established niche
products and it currently owns or licenses the rights to
approximately 90 pharmaceutical and consumer healthcare products.
The Company continues to explore opportunities to expand its
product portfolio.
Alliance joined the AIM market of the London Stock Exchange in
December 2003 and trades under the symbol APH.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORPBMFTMBIMBAF
(END) Dow Jones Newswires
August 02, 2016 02:01 ET (06:01 GMT)
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Sep 2023 to Sep 2024